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Nonocclusive Coronary
Dissections: To Stent or Not to Stent?
Cappelletti et al. (1) reviewed the outcome of 129 consecutive
patients treated with conventional angioplasty (PTCA) at a time
when coronary stents were not available. Patients (45; 35%)
presenting nonocclusive dissections post-PTCA had a significantly
lower restenosis rate than patients without dissections (12% vs.
44%; p , 0.001). The restenosis rate in another group of patients
undergoing stenting for nonocclusive dissection (clinically and
angiographically matched), later on in their experience, was 25%
(1). At a time when coronary stenting is experiencing an exponen-
tial increase, these results would appear rather provocative. Some
classical studies, however, also suggested that most dissections are
not only benign but also predict a lower restenosis rate (2,3).
Nevertheless, no previous study was able to demonstrate such a low
restenosis rate in this cohort of patients.
Furthermore, to demonstrate convincingly that a conservative
approach—namely a “watchful waiting” strategy—may even be
superior in the long run to coronary stenting is much more
challenging. Given the potential clinical implications of this study,
some methodological clarifications appear warranted.
First, it is not clear why two patients with vessel closure were
excluded. Keeping in mind that this is a retrospective study, it will
be important to know whether these dissections were flow-limiting
immediately after PTCA or flow deterioration occurred later on.
Second, 67% (33/49) of the nontreated dissections were type A
versus none (0/60) of the stented dissections (chi-square p ,
0.0001). Therefore, it is difficult to assume that these two popu-
lations were similar, and thus direct comparison of results may not
be appropriate. Further details on whether the restenosis rate
tended to cluster around patients with type C-D dissections
(untreated/stented groups) will be helpful.
Finally, the methodology of quantitative coronary analysis was
not specified. This is relevant because the analysis of dissected
coronary segments is technically demanding. In fact, at first glance
it appears difficult to explain a mean lumen diameter post-PTCA
of 3.23 6 0.65 mm (reference 3.20 6 0.54 mm) yielding a 20 6
7% diameter stenosis. The large lumen diameter of the dissected
segments indicates that the dissection image was fully included
into the lumen measurements. This is in contradistinction with
some prior studies using careful edge-detection quantitative an-
giography (4,5). We previously demonstrated (5) that residual
coronary dissections after stenting had a benign outcome when
they were stable, were not associated with significant lumen
narrowing, and did not compromise coronary flow.
Our data (5) also concur with the current study, suggesting that
most residual dissections disappear at follow-up. Moreover, these
dissected coronary segments may promote a unique pattern of
vessel remodeling that could explain a lower restenosis rate (1) or
even a significant lumen improvement on late angiography (5). We
fully agree with the idea that conservative management of coronary
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dissections is attractive in selected cases (adverse anatomy, small
vessels, type A-B dissections). However, we believe that only
properly designed studies will be able to determine whether this
strategy is superior to stenting in most patients experiencing
nonocclusive dissections. In the interim, accepting the potential
risk of vessel closure and the logistic implications (prolonged
observation or even repeat angiography) inherently associated with
the conservative strategy should be weighted against the results of
coronary stenting using currently available stent designs. Although
we sympathize with the words of caution against the indiscrimi-
nate use of stents, it would appear more reasonable to challenge
first the systematic use of “elective” stenting in clinical/
angiographic settings where its efficacy—as compared with
PTCA—remains largely unsettled.
Fernando Alfonso, MD, PhD, FESC
Interventional Cardiology Department
San Carlos University Hospital
Madrid, Spain
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REPLY
Dr. Alfonso asks why two patients in our study (1) with occlusive
dissection after percutaneous transluminal coronary angioplasty
(PTCA) were excluded and when these dissections occurred. As it
is clearly stated in the article these two type E dissections evolved
toward complete artery occlusion during the procedure and how
they caused an acute myocardial infarction immediately after the
procedure. Because the study reported the results of nonocclusive
unstented dissections, they were excluded from the analysis at the
beginning.
As far as the second point is concerned, we have acknowledged
the higher prevalence of lesions A and B in the unstented group,
but this limitation derives from the later stage in which the stented
patients were assessed, when the easy availability of stenting
allowed higher inflation pressures. However, although unstented
patients had a higher prevalence of dissections grades A and B
(namely 85% vs. 56% at 24 h), the restenosis rate for stented and
unstented patients was similar for each dissection grade (p 5 NS).
What we would like to stress in our study is that in this stenting
era, where there is a growing and widespread use of these devices
(2), the “minor” dissections (type A and B), most frequently
occurring during PTCA, are associated with a very low risk of
complications and restenosis, suggesting a more conservative
approach.
Finally, Dr. Alfonso states that “the large lumen diameter of the
dissected segments indicates that the dissection image was fully
included into the lumen measurements.” However, as clearly
shown in Table 1 of our article, the mean lumen diameter
post-PTCA in dissected vessels was not 3.23 6 0.65 mm but
3.11 6 0.89 mm, a lower value than that of the mean reference
artery diameter pre-PTCA (3.18 6 0.7 mm) in the same vessels.
We do agree that the methodology of quantitative coronary
angiography is technically demanding, especially for the analysis of
dissected segments. Therefore, we are promoting in our Institute
new and different tools for quantitative analysis, such as intracoro-
nary ultrasound (IVUS), coronary Doppler evaluation, and myo-
cardial fractional flow-reserve measurement.
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Coenzyme Q10 as an Adjunctive Therapy
in Patients With Congestive Heart Failure
Lack of effect from treatment with coenzyme Q10 in congestive
heart failure is not an objective title or conclusion for the study by
Watson et al. (1) in which the main limitation obviously is their
sample size and its lack of study patients. Even so, the investigators
state in their introduction that previous studies with coenzyme
Q10 “lack credibility because of small sample sizes, lack of
controls, etc.”
The majority of the 27 study patients, who were not classified
according to the New York Heart Association (NYHA), were
seemingly at late-stage disease (mean length of symptoms 3.4
years). Mean patient age was 55 years, which is compatible with
predominantly ischemic origin. This was also recently confirmed at
an International Conference in Sydney, Australia—“Oxidative
Pathways in Health and Disease”—in a lecture by one of the
co-authors, Nicholas Bett (2). However, according to the Watson
et al. (1) study, in the Patients’ Demographics in Table 1, 77% of
the patients were listed as having dilated cardiomyopathy. This is
a patient clientele that is, at least partially, prone to respond either
spontaneously or to medical intervention with subsequent im-
provement of myocardial function.
Conversely, it is well-known that changes—and not least
improvements—in echocardiographic parameters of left ventricu-
lar (LV) function are minimal in late-stage disease, especially in
heart failure due to ischemic heart disease. This is why the
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